The role of proteomics in the diagnosis of chorioamnionitis and early-onset neonatal sepsis

Clinics in Perinatology

Volumn 37, Issue 2, 2010, Pages 355-374

  Buhimschi, Irina A ^a   Buhimschi, Catalin S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; DAMPs; Newborn; Proteomics; RAGE; Sepsis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; DEFENSIN; DNA; GLUCOSE; INTERLEUKIN 6; LACTATE DEHYDROGENASE; PROTEIN S 100; RNA;

AFFINITY CHROMATOGRAPHY; AMNION FLUID ANALYSIS; BACTERIUM CULTURE; BACTEROIDES; BRAIN HEMORRHAGE; CEREBRAL PALSY; CHORIOAMNIONITIS; DIAGNOSTIC VALUE; DNA DETERMINATION; GARDNERELLA VAGINALIS; GRAM STAINING; HUMAN; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; INTRAUTERINE INFECTION; ION EXCHANGE CHROMATOGRAPHY; ISOELECTRIC FOCUSING; LEUKOCYTE COUNT; MASS SPECTROMETRY; MOLECULAR MECHANICS; MYCOPLASMA HOMINIS; NEWBORN SEPSIS; PATHOPHYSIOLOGY; PEPTOSTREPTOCOCCUS; POLYMERASE CHAIN REACTION; PREDICTION; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UREAPLASMA; WESTERN BLOTTING; DIFFERENTIAL DIAGNOSIS; FEMALE; IMMUNOLOGY; INNATE IMMUNITY; MICROBIOLOGY; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PROCEDURES; SEPSIS; SIGNAL TRANSDUCTION;

BIOLOGICAL MARKERS; CHORIOAMNIONITIS; DEFENSINS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNITY, INNATE; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROTEOMICS; RISK FACTORS; SEPSIS; SIGNAL TRANSDUCTION;

EID: 77953527633     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2010.03.002     Document Type: Review

References (95)

1. International Human Genome Sequencing Consortium Initial sequencing and analysis of the human genome. Nature 2001, 409(6822):860-921.
2. Anderson L., Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997, 18:533-537.
3. Ghildiyal M., Zamore P.D. Small silencing RNAs: an expanding universe. Nat Rev Genet 2009, 10(2):94-108.
4. Piekarska B., Rybarska J., Stopa B., et al. Supramolecularity creates nonstandard protein ligands. Acta Biochim Pol 1999, 46(4):841-851.
5. Hoogland C., Mostaguir K., Sanchez J.C., et al. SWISS-2DPAGE, ten years later. Proteomics 2004, 4(8):2352-2356.
6. Apweiler R., Aslanidis C., Deufel T., et al. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med 2009, 47(6):724-744.
7. Buhimschi I.A., Buhimschi C.S. Proteomics of the amniotic fluid in assessment of the placenta. Relevance for preterm birth. Placenta 2008, 29(Suppl A):S95-101.
8. Buhimschi IA. Using SELDI-TOF mass spectrometry for clinical proteomics of amniotic fluid and future theranostics. Methods Mol Biol 2010, in press.
9. Petricoin E.E., Paweletz C.P., Liotta L.A. Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia 2002, 7(4):433-440.
10. Nesvizhskii A.I. Protein identification by tandem mass spectrometry and sequence database searching. Methods Mol Biol 2007, 367:87-119.
11. Kitteringham N.R., Jenkins R.E., Lane C.S., et al. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(13):1229-1239.
12. Weinberger S.R., Morris T.S., Pawlak M. Recent trends in protein biochip technology. Pharmacogenomics 2000, 1(4):395-416.
13. Fung E.T., Enderwick C. ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques 2002, 32(Suppl 1):34-41.
14. Langbein S. Identification of disease biomarkers by profiling of serum proteins using SELDI-TOF mass spectrometry. Methods Mol Biol 2008, 439:191-197.
15. Buhimschi I.A., Christner R., Buhimschi C.S. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. BJOG 2005, 112(2):173-181.
16. Buhimschi I.A., Zhao G., Funai E.F., et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am J Obstet Gynecol 2008, 199(5):551. e1-16.
17. Buhimschi C.S., Bhandari V., Dulay A.T., et al. Comprehensive proteomic mapping of cord blood to identify novel biomarkers and functional protein networks characteristic of early-onset neonatal sepsis (EONS). Am J Obstet Gynecol 2008, 199(6A):S3.
18. Buhimschi C.S., Bhandari V., Hamar B.D., et al. Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis. PLoS Med 2007, 4(1):e18.
19. Buhimschi C.S., Buhimschi I.A., Abdel-Razeq S., et al. Proteomic biomarkers of intra-amniotic inflammation: relationship with funisitis and early-onset sepsis of the premature neonate. Pediatr Res 2007, 61:318-324.
20. Buhimschi I.A., Zambrano E., Pettker C.M., et al. Using proteomic analysis of the human amniotic fluid to identify histologic chorioamnionitis. Obstet Gynecol 2008, 111(2 Pt 1):403-412.
21. Han Y.W., Shen T., Chung P., et al. Uncultivated bacteria as etiologic agents of intra-amniotic inflammation leading to preterm birth. J Clin Microbiol 2009, 47(1):38-47.
22. Weiner C.P., Lee K.Y., Buhimschi C.S., et al. Proteomic biomarkers that predict the clinical success of rescue cerclage. Am J Obstet Gynecol 2005, 192(3):710-718.
23. Norwitz E.R., Tsen L.C., Park J.S., et al. Discriminatory proteomic biomarker analysis identifies free hemoglobin in the cerebrospinal fluid of women with severe preeclampsia. Am J Obstet Gynecol 2005, 193(3 Pt 2):957-964.
24. Buhimschi I.A., Buhimschi C.S., Zhao G.M., et al. Mass spectrometry-a novel approach in deciphering the origin and duration of intra-amniotic bleeding. Am J Obstet Gynecol 2005, 193(6):S107.
25. Buhimschi I.A., Zhao G., Abdel-Razeq S., et al. Multidimensional proteomics analysis of the amniotic fluid to provide insight into the mechanisms of idiopathic preterm birth. PLoS One 2008, 3(4):e2049.
26. Ng P.C., Lam H.S. Diagnostic markers for neonatal sepsis. Curr Opin Pediatr 2006, 18(2):125-131.
27. Smulian J.C., Bhandari V., Campbell W.A., et al. Value of umbilical artery and vein levels of interleukin-6 and soluble intracellular adhesion molecule-1 as predictors of neonatal hematologic indices and suspected early sepsis. J Matern Fetal Med 1997, 6(5):254-259.
28. Gonzalez B.E., Mercado C.K., Johnson L., et al. Early markers of late-onset sepsis in premature neonates: clinical, hematological and cytokine profile. J Perinat Med 2003, 31(1):60-68.
29. Bizzarro M.J., Dembry L.M., Baltimore R.S., et al. Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics 2008, 121(4):689-696.
30. Murphy D.J., Sellers S., MacKenzie I.Z., et al. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet 1995, 346(8988):1449-1454.
31. Martius J.A., Roos T., Gora B., et al. Risk factors associated with early-onset sepsis in premature infants. Eur J Obstet Gynecol Reprod Biol 1999, 85(2):151-158.
32. Wenstrom K.D., Andrews W.W., Hauth J.C., et al. Elevated second-trimester amniotic fluid interleukin-6 levels predict preterm delivery. Am J Obstet Gynecol 1998, 178(3):546-550.
33. Dammann O., Leviton A. Role of the fetus in perinatal infection and neonatal brain damage. Curr Opin Pediatr 2000, 12:99-104.
34. Jacobsson B., Mattsby-Baltzer I., Andersch B., et al. Microbial invasion and cytokine response in amniotic fluid in a Swedish population of women with preterm prelabor rupture of membranes. Acta Obstet Gynecol Scand 2003, 82:423-431.
35. Motterlini R., Foresti R., Vandegriff K., et al. Oxidative-stress response in vascular endothelial cells exposed to acellular hemoglobin solutions. Am J Physiol 1995, 269(2 Pt 2):H648-H655.
36. Muglia L.J., Katz M. The enigma of spontaneous preterm birth. N Engl J Med 2010, 362(6):529-535.
37. Moberg L.J., Garite T.J., Freeman R.K. Fetal heart rate patterns and fetal distress in patients with preterm premature rupture of membranes. Obstet Gynecol 1984, 64(1):60-64.
38. Hauth J.C., Gilstrap L.C., Hankins G.D., et al. Term maternal and neonatal complications of acute chorioamnionitis. Obstet Gynecol 1985, 66(1):59-62.
39. Angus S.R., Segel S.Y., Hsu C.D., et al. Amniotic fluid matrix metalloproteinase-8 indicates intra-amniotic infection. Am J Obstet Gynecol 2001, 185(5):1232-1238.
40. Andrews W.W., Goldenberg R.L., Hauth J.C. Preterm labor: emerging role of genital tract infections. Infect Agents Dis 1995, 4(4):196-211.
41. Goldenberg R.L., Hauth J.C., Andrews W.W. Intrauterine infection and preterm delivery. N Engl J Med 2000, 342(20):1500-1517.
42. Markenson G., Martin R., Foley K., et al. The use of polymerase chain reaction to detect bacteria in amniotic fluid in pregnancies complicated with preterm labor. Am J Obstet Gynecol 1997, 177(6):1471-1477.
43. Larsen J.W., Sever J.L. Group B Streptococcus and pregnancy: a review. Am J Obstet Gynecol 2008, 198(4):440-448.
44. Pettker C.M., Buhimschi I.A., Magloire L.K., et al. Value of placental microbial evaluation in diagnosing intra-amniotic infection. Obstet Gynecol 2007, 109(3):739-749.
45. Barron E.J., Jorgensen J.H., Landry M.L., et al. Bacteriology. Manual of clinical bacteriology 2007, 974. ASM Press, Washington, DC. 9th edition. P.R. Murray (Ed.).
46. Dong J., Olano J.P., McBride J.W., et al. Emerging pathogens: challenges and successes of molecular diagnostics. J Mol Diagn 2008, 10(3):185-197.
47. Kuypers M.M. Microbiology. Sizing up the uncultivated majority. Science 2007, 317(5844):1510-1511.
48. Hitti J., Riley D.E., Krohn M.A., et al. Broad-spectrum bacterial rDNA polymerase chain reaction assay for detecting amniotic fluid infection among women in premature labor. Clin Infect Dis 1997, 24(6):1228-1232.
49. Gravett M.G., Novy M.J., Rosenfeld R.G., et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 2004, 292(4):462-469.
50. Ruetschi U., Rosen A., Karlsson G., et al. Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J Proteome Res 2005, 4(6):2236-2242.
51. Sampson J.E., Theve R.P., Blatman R.N., et al. Fetal origin of amniotic fluid polymorphonuclear leukocytes. Am J Obstet Gynecol 1997, 176(1):77-81.
52. Buhimschi I.A., Buhimschi C.S., Norwitz E., et al. Proteomic analysis of cervico-vaginal secretions during pregnancy. Am J Obstet Gynecol 2004, 191(6):S137.
53. Di Quinzio M.K., Oliva K., Holdsworth S.J., et al. Proteomic analysis and characterisation of human cervico-vaginal fluid proteins. Aust N Z J Obstet Gynaecol 2007, 47(1):9-15.
54. Shaw J.L., Smith C.R., Diamandis E.P. Proteomic analysis of human cervico-vaginal fluid. J Proteome Res 2007, 6(7):2859-2865.
55. Gravett M.G., Thomas A., Schneider K.A., et al. Proteomic analysis of cervical-vaginal fluid: identification of novel biomarkers for detection of intra-amniotic infection. J Proteome Res 2007, 6(1):89-96.
56. Cobo T., Palacio M., Navarro-Sastre A., et al. Predictive value of combined amniotic fluid proteomic biomarkers and interleukin-6 in preterm labor with intact membranes. Am J Obstet Gynecol 2009, 200(5):499. e1-6.
57. Goldenberg R.L., Andrews W.W., Goepfert A.R., et al. The Alabama preterm birth study: umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am J Obstet Gynecol 2008, 198(1):e1-e5.
58. Redline R.W. Placental pathology and cerebral palsy. Clin Perinatol 2006, 33(2):503-516.
59. Bejar R., Wozniak P., Allard M., et al. Antenatal origin of neurologic damage in newborn infants. I. Preterm infants. Am J Obstet Gynecol 1988, 159(2):357-363.
60. De Felice C., Toti P., Laurini R.N., et al. Early neonatal brain injury in histologic chorioamnionitis. J Pediatr 2001, 138(1):101-104.
61. Grafe M.R. The correlation of prenatal brain damage with placental pathology. J Neuropathol Exp Neurol 1994, 53(4):407-415.
62. Yancey M.K., Duff P., Kubilis P., et al. Risk factors for neonatal sepsis. Obstet Gynecol 1996, 87(2):188-194.
63. Buttery J.P. Blood cultures in newborns and children: optimising an everyday test. Arch Dis Child Fetal Neonatal Ed 2002, 87(1):F25-F28.
64. Jordan J.A., Durso M.B., Butchko A.R., et al. Evaluating the near-term infant for early-onset sepsis: progress and challenges to consider with 16S rDNA polymerase chain reaction testing. J Mol Diagn 2006, 8(3):357-363.
65. Rodwell R.L., Leslie A.L., Tudehope D.I. Early diagnosis of neonatal sepsis using a hematologic scoring system. J Pediatr 1988, 112(5):761-767.
66. Rodwell R.L., Taylor K.M., Tudehope D.I., et al. Hematologic scoring system in early diagnosis of sepsis in neutropenic newborns. Pediatr Infect Dis J 1993, 12(5):372-376.
67. Miller M.E. Host defenses in the human neonate. Pediatr Clin North Am 1977, 24(2):413-423.
68. ACOG Committee on Practice Bulletins-Obstetrics ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 2007, 109(4):1007-1019.
69. American College of Obstetricians and Gynecologists ACOG Committee Opinion: number 279, December 2002. Prevention of early-onset group B streptococcal disease in newborns. Obstet Gynecol 2002, 100(6):1405-1412.
70. Kenyon S.L., Taylor D.J., Tarnow-Mordi W., et al. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group. Lancet 2001, 357:979-988.
71. Kenyon S.L., Taylor D.J., Tarnow-Mordi W., et al. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. Lancet 2001, 357:989-994.
72. Stoll B.J., Hansen N., Fanaroff A.A., et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002, 347:240-247.
73. Gravett M.G., Adams K.M., Sadowsky D.W., et al. Immunomodulators plus antibiotics delay preterm delivery after experimental intraamniotic infection in a nonhuman primate model. Am J Obstet Gynecol 2007, 197(5):518. e1-8.
74. Buhimschi C.S., Abdel-Razeq S., Cackovic M., et al. Fetal heart rate monitoring patterns in women with amniotic fluid proteomic profiles indicative of inflammation. Am J Perinatol 2008, 25(6):359-372.
75. Pétrilli V., Dostert C., Muruve D.A., et al. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007, 19(6):615-622.
76. Lotze M.T., Zeh H.J., Rubartelli A., et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007, 220:60-81.
77. Sonoi H., Matsumoto N., Ogura H., et al. The effect of antithrombin on pulmonary endothelial damage induced by crush injury. Shock 2009, 32(6):593-600.
78. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418(6894):191-195.
79. Ombrellino M., Wang H., Ajemian M.S., et al. Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet 1999, 354(9188):1446-1447.
80. Yang H., Tracey K.J. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010, 1799(1-2):149-156.
81. Hofmann M.A., Drury S., Fu C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97(7):889-901.
82. Chavakis T., Bierhaus A., Al-Fakhri N., et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003, 198(10):1507-1515.
83. Yan S.F., Ramasamy R., Naka Y., et al. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003, 93(12):1159-1169.
84. Lutterloh E.C., Opal S.M. Antibodies against RAGE in sepsis and inflammation: implications for therapy. Expert Opin Pharmacother 2007, 8(9):1193-1196.
85. Lutterloh E.C., Opal S.M., Pittman D.D., et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007, 11(6):R122.
86. Yang H., Ochani M., Li J., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004, 101(1):296-301.
87. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5(4):331-342.
88. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285(5425):248-251.
89. Buhimschi I.A., Zhao G., Pettker C.M., et al. The receptor for advanced glycation end products (RAGE) system in women with intraamniotic infection and inflammation. Am J Obstet Gynecol 2007, 196(2):181. e1-181.e13.
90. Buhimschi C.S., Baumbusch M.A., Dulay A.T., et al. Characterization of RAGE, HMGB1 and S100β in inflammation induced preterm birth and fetal tissue injury. Am J Pathol 2009, 175(3):958-975.
91. Buhimschi C.S., Buhimschi I.A. Proteomic biomarkers of adverse pregnancy outcome in preterm birth - a theranostics opportunity. Expert Rev Obstet Gynecol 2007, 2(6):743-753.
92. Heizmann C.W., Ackermann G.E., Galichet A. Pathologies involving the S100 proteins and RAGE. Subcell Biochem 2007, 45:93-138.
93. Buhimschi C.S., Rosenberg V.A., Dulay A.T., et al. Multidimensional system biology: genetic markers and proteomic biomarkers of adverse pregnancy outcome in preterm birth. Am J Perinatol 2008, 25(3):175-187.
94. Holzheimer R.G. Antibiotic induced endotoxin release and clinical sepsis: a review. J Chemother 2001, 1(1):159-172.
95. Klebanoff M.A., Carey J.C., Hauth J.C., et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001, 345(7):487-493.